TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03149406

Intervention type: OTHER
Intervention: Comparing the expression of miRNAs
Description: by PCR, in symptomatic and asymptomatic carotid plaques.

Intervention type: OTHER
Intervention: Comparing the expression of miRNAs
Description: by PCR, in symptomatic and asymptomatic carotid plaques.
Study: NCT02867046

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: S1 transforaminal epidural steroid(dexamethasone) injection
Description: medial approach group (n=85): check intravascular injection while performing S1 transforaminal epidural steroid(dexamethasone) injection in medial side of S1 foramen under fluoroscopy~lateral approach group (n=85): same as medial approach group except using lateral side of S1 foramen

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: S1 transforaminal epidural steroid(dexamethasone) injection
Description: medial approach group (n=85): check intravascular injection while performing S1 transforaminal epidural steroid(dexamethasone) injection in medial side of S1 foramen under fluoroscopy~lateral approach group (n=85): same as medial approach group except using lateral side of S1 foramen
Study: NCT01254981

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Description: Implantation of coronary stent
Study: NCT03492463

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Non-nicotine e-cigarettes
Description: Participants will use e-cigarettes not containing nicotine while switching from cigarette use to use of e-cigarettes for eight weeks.
Study: NCT01048190

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (Sabin strains)
Description: 15 infants received 3 doses of formulation C vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (Sabin strains)
Description: 15 infants received 3 doses of formulation B vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart;

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated Poliomyelitis Vaccine (Sabin strains)
Description: 15 infants received 3 doses of formulation A vaccine and 15infants received 3 doses of placebo 3x0.5ml intramuscular injections, one month apart.
Study: NCT05437224

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Description: eligible subjects received 5 mg ambrisentan orally once daily for a 12-week primary evaluation period. Subjects then proceeded to a 12-week dose adjustment period during which dose titration to 10 mg was allowed.
Study: NCT02426658

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed Disodium
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: QOL studies
Study: NCT04516018

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cold exposure
Description: Subjects will be exposed to shivering thermogenesis for at least 1 hour for 10 days
Study: NCT05809882

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Magstim RAPID2 neuromagnetic stimulator (Magstim) with an 8-type coil
Description: frequency range, 20 Hz; 90% motion threshold; 3 s of stimulation; a 57 s interval; 15 min of stimulation for each side, five times per week for a total of 20 times

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Magstim RAPID2 neuromagnetic stimulator (Magstim) with an 8-type coil
Description: frequency range, 20 Hz，60% motion threshold; 3 s of stimulation; a 57 s interval; 15 min of stimulation for each side, five times per week for a total of 20 times. But with no stimulating energy output.
Study: NCT00395681

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprivan
Description: Propofol 200 mg versus 350 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diprivan
Description: Propofol 200 mg versus 350 mg
Study: NCT00567307

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Red Heart Pill 2b (Polypill)
Description: Arm A will receive the polypill (Red Heart pill 2b) which is a combination of aspirin (75 mg), simvastatin (20g), lisinopril (10mg) and hydrochlorothiazide (12.5 mg)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Practice
Description: Arm B will receive management of their CVD risk according to the usual care given to participants in similar conditions
Study: NCT02520570

Intervention type: DRUG
Intervention: ulinastatin
Description: We wouldn't intervene the doctors how to treat with the patients or how to use the drug, we just observe the react of patients after treated with ulinastatin.

Intervention type: DRUG
Intervention: ulinastatin
Description: We wouldn't intervene the doctors how to treat with the patients or how to use the drug, we just observe the react of patients after treated with ulinastatin.
Study: NCT02155829

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Riluzole

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (for Riluzole)
Study: NCT02834689

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: Walking on a treadmill at 3.5 METS for 50 minutes

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Seated Control
Description: Sitting for 50 minutes
Study: NCT04564313

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Camrelizumab treatment
Description: Camrelizumab (SHR-1210), 200mg, I.V., Q3W
Study: NCT01085279

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fraxel Restore, Solta Medical Inc. (Non-ablative fractional laser)
Description: 1,550 nm non-ablative fractional laser Irradiance: 15 mJ/microbeam. Coverage: 14-20%. Number of treatment sessions: 4-5
Study: NCT04417751

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Stimulation
Description: The intervention includes 50 sessions, over the course of one year, being that 3 of those sessions will be the pretest, intratest and posttest evaluations. The intervention sessions will last approximately 45 minutes and they will be developed according to the following structure: welcoming and greeting the participants (5 minutes); reality orientation therapy (10 minutes), cognitive stimulation \[CS\] activity (25 minutes); return to calm and closure of the session, and session evaluation (5 minutes). CS sessions will be conducted in an individual intervention format. The intervention sessions will include several activities based on different non-pharmacological therapies (e.g., reminiscence therapy, reality orientation therapy, cognitive training) whose effectiveness in older adults with neurocognitive disorders has been scientifically proven. All individual CS sessions will be conducted by one therapist (clinical psychologist) with more than five years of experience in CS.
Study: NCT01085279

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Modified Kligman's formula (Triple topical therapy)
Description: Hydroquinone 5%, tretinoin 0.05%, triamcinolone acetonide 0.1% once a day during 15 weeks
Study: NCT02057354

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Aerobic Exercise
Description: The goal of the aerobic exercise training is to increase aerobic endurance. Walking on treadmill at moderate intensity with grade adjusted. Exercise tailored to individual ability level.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Aerobic Exercise
Description: The goal of the aerobic exercise training is to increase aerobic endurance. Walking on treadmill at moderate intensity with grade adjusted. Exercise tailored to individual ability level.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Non-Aerobic Exercise
Description: The goal of this training is to improve overall muscle strength, balance and flexibility. Participants will do strength, balance and stretching exercises. Exercises tailored to individual ability level.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Non-Aerobic Exercise
Description: The goal of this training is to improve overall muscle strength, balance and flexibility. Participants will do strength, balance and stretching exercises. Exercises tailored to individual ability level.
Study: NCT04007302

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: measurement of bilateral activity of the prefrontal cortex by a NIRS system (near infrared spectroscopy)
Description: measurement of the cerebral oxygenation response by the use of the Near Infrared Spectroscopy (NIRS) method

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: measurement of bilateral activity of the prefrontal cortex by a NIRS system (near infrared spectroscopy)
Description: measurement of the cerebral oxygenation response by the use of the Near Infrared Spectroscopy (NIRS) method

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: completion of questionnaires
Description: igroup presence questionnaire (IPQ), Dallas Pain Questionnaire (DRAD), Fear-Avoidance Beliefs (FABQ) and Quebec Back Lumbago Scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: completion of questionnaires
Description: igroup presence questionnaire (IPQ), Dallas Pain Questionnaire (DRAD), Fear-Avoidance Beliefs (FABQ) and Quebec Back Lumbago Scale
Study: NCT04143282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin plus chemotherapy
Description: determine the effect of metformin along with standard chemotherapy

Intervention type: DRUG
Group type: OTHER
Intervention: Chemotherapy
Description: standard chemotherapy
Study: NCT04172025

Intervention type: DIAGNOSTIC_TEST
Intervention: Analysis of Bacterial Genome
Description: genome assembly; prediction of sequence type (MLST); core genome MLST tree to rapidly compare strains within a project; core genome single nucleotide polymorphism (SNP) tree to compare all Swiss Pathogen Surveillance Platform (SPSP) strains belonging to a same species; whole genome SNP tree to compare all SPSP strains within the same species and ST;; prediction of resistance and virulence factors within pathogen submitted genomes; time trees and calculation of transmission rates, including basic reproduction number; analysis of classical epidemiological data with advanced statistical methods including machine learning.
Study: NCT00758563

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triclosan/Fluoride
Description: Brush twice daily
Study: NCT01990690

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: anti oxidant omega 3
Description: Soft gelatineous capsule (Sedico medical company) each capsule contains:~* Fish oil (30) % (Eicosapentaenoic acid (EPA) 18 % / Docosahexaenoic acid (DHA) 12 % ) natural source of Omega 3 Fatty acids.~* Wheat germ oil (Tocopherol: N.N.T. 0.22 %) which is rich and natural source of Vitamin E (protects the oils from oxidation. besides its well known that requirements of vitamin E increases with increased dietary amounts of polyunsaturated fatty acids).~Group 1 was given omega -3 plus (Sedico medical company) as antioxidant once daily for two weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: anti oxidant omega 3
Description: Soft gelatineous capsule (Sedico medical company) each capsule contains:~* Fish oil (30) % (Eicosapentaenoic acid (EPA) 18 % / Docosahexaenoic acid (DHA) 12 % ) natural source of Omega 3 Fatty acids.~* Wheat germ oil (Tocopherol: N.N.T. 0.22 %) which is rich and natural source of Vitamin E (protects the oils from oxidation. besides its well known that requirements of vitamin E increases with increased dietary amounts of polyunsaturated fatty acids).~Group 1 was given omega -3 plus (Sedico medical company) as antioxidant once daily for two weeks.
Study: NCT00567554

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin - cyclophosphamide / docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epirubicin - cyclophosphamide / docetaxel + bevacizumab

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel + everolimus (RAD001)
Study: NCT04007302

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: completion of questionnaires for pain
Description: analogical visual and numerical scale and Borg scale

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: completion of questionnaires for pain
Description: analogical visual and numerical scale and Borg scale
Study: NCT00678795

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex®
Description: Containing ∆9 tetrahydrocannabinol (THC), 27 mg/ml and cannabidiol (CBD), 25 mg/ml as extract of Cannabis sativa L.~Subjects received study medication delivered in 100 µl actuations by a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations (THC 130 mg:CBD 120 mg) in 24 hours

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: containing excipients only. Subjects received study medication delivered in 100 µl actuations from a pump action oromucosal spray. Maximum permitted dose was eight actuations in any three-hour period and 48 actuations in 24 hours.
Study: NCT03724370

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Telehealth Monitoring System
Description: TES will be conducted daily via Interactive Voice Response System (IVRS) during the 12 week study period.TES will be added to VHA-SRM.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VHA-SRM
Description: Veterans Health Administration Suicide Risk Management supportive services will be provided to participant during the 12 weeks of study participation.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: VHA-SRM
Description: Veterans Health Administration Suicide Risk Management supportive services will be provided to participant during the 12 weeks of study participation.
Study: NCT03203798

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Training of pelvic floor muscles
Description: The pelvic floor muscle training group will be composed of randomized women and participated for 12 weeks of intervention, where it was performed in groups of a maximum of 4 patients, starting in the first 4 weeks with 3 sets of 8 repetitions of contraction maintained for 5 seconds In antigravity postures, with two lying postures and one sitting posture, and evolving to the next 4 weeks for 3 sets with 10 repetitions of contraction maintained for 5 seconds being a lying posture, a seated posture and orthostatic posture in the last 4 weeks 3 Series of 12 repetitions of contraction maintained for 5 seconds in the gravitational postures, being one sitting posture and two orthostatic postures.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hipopressive abdominal gymnastics
Description: The hipopressiva abdominal gymnastics group will be composed of randomized women who participated for 12 weeks of intervention, where it was performed in groups of a maximum of 4 patients, being performed respecting the basic sequence of the exercise proposed by Marcel Caufriez: 1) Inspiration, 2) Maximum Expiration, 3) Diaphragmatic aspiration being performed 3 series of 8 to 12 repetitions. The exercises will be performed in groups of a maximum of 4 patients, starting in the first 4 weeks with 3 sets of 8 repetitions in antigravity postures, with two lying postures and one sitting posture, and evolving over the next 4 weeks to 3 sets with 10 repetitions A lying posture, a sitting posture and orthostatic posture, in the last 4 weeks 3 sets of 12 repetitions in the gravitational postures, being a sitting posture and two orthostatic postures.
Study: NCT04107805

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 1323495
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Midazolam
Description: Oral administration
Study: NCT00768131

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Vial, Intravenous, 400 mg/m² week 1 then 250 mg/m², Weekly, Until PD/Toxicity/Pt-PI Decision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Vial, Intravenous, 400 mg/m² week 1 then 250 mg/m², Weekly, Until PD/Toxicity/Pt-PI Decision

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Vial, Intravenous, 225 mg/m2, Every 3 weeks, 6 cycles maximum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Paclitaxel
Description: Vial, Intravenous, 225 mg/m2, Every 3 weeks, 6 cycles maximum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Vial, Intravenous, 225 mg/m2, Every 3 weeks, 6 cycles maximum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Paclitaxel
Description: Vial, Intravenous, 225 mg/m2, Every 3 weeks, 6 cycles maximum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Vial, Intravenous, AUC = 6.0, Every 3 weeks, 6 cycles maximum

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Vial, Intravenous, AUC = 6.0, Every 3 weeks, 6 cycles maximum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Vial, Intravenous, AUC = 6.0, Every 3 weeks, 6 cycles maximum

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Carboplatin
Description: Vial, Intravenous, AUC = 6.0, Every 3 weeks, 6 cycles maximum
Study: NCT03960983

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Treatment with tongue scraper
Description: Treatment with tongue scraper. the evaluation of halitosis will be repeated before this step.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hygiene procedures for the mucosa and dentures
Description: Hygiene procedures for the mucosa and dentures edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis will be repeated before this step

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Photodynamic Therapy
Description: Treatment with Photodynamic therapy. The evaluation of halitosis will be repeated before this step

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hygiene procedures for the mucosa and dentures
Description: Hygiene procedures for the mucosa and dentures edentulous participants will be submitted to hygiene procedures for the mucosa and dentures. The evaluation of halitosis will be repeated before this step
Study: NCT03260205

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to SPD489 (Lisdexamfetamine dimesylate) capsule for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489 (Lisdexamfetamine dimesylate)
Description: SPD489 capsule in a 5:5:5:5:6 ratio to 5, 10, 20, 30 mg orally once daily for 6 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPD489
Description: SPD489
Study: NCT04008589

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive transorbital AC Stimulation
Description: Repetitive transorbital ACS with max 30 Hz, 1,5 mA for 10 days, 20 min/day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transorbital AC Stimulation
Description: Repetitive transorbital ACS with max 30 Hz, 1,5 mA for 10 days, 20 min/day

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive transorbital AC Stimulation
Description: Repetitive transorbital ACS with max 30 Hz, 1,5 mA for 10 days, 20 min/day

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: combination of transcranial direct current stimulaton and rtACS
Description: Sequential tDCS (anodal occipital stimulation with 2 mA for 20 min/day for 10 days) and rtACS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: combination of transcranial direct current stimulaton and rtACS
Description: Sequential tDCS (anodal occipital stimulation with 2 mA for 20 min/day for 10 days) and rtACS

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: combination of transcranial direct current stimulaton and rtACS
Description: Sequential tDCS (anodal occipital stimulation with 2 mA for 20 min/day for 10 days) and rtACS
Study: NCT01532323

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Taking of saliva before and after gustatory stimulation
Description: Taking of saliva before and after gustatory stimulation (3 drops of citric acid 2.4 g / L)

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Taking of saliva before and after gustatory stimulation
Description: Taking of saliva before and after gustatory stimulation (3 drops of citric acid 2.4 g / L)